Trademarkia Logo

Canada

C$
Trademark Search in Canada
PEDIAVANT

View On IC.GC.CA

PEDIAVANT
REGISTERED

on 6 Dec 2022

Last Applicant/ Owned by

ROIVANT SCIENCES GMBH

Viaduktstrasse 84051 Basel

CH

Serial Number

1941251 filed on 17th Jan 2019

Registration Number

TMA1154749 registered on 6th Dec 2022

Registration expiry Date

6th Dec 2032

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

PEDIAVANT

Trademark usage description

pharmaceutical preparations for human use for the treatment of diseases, disorders and conditions related to pediatrics and neonatology, namely, respi Read More

Classification Information

Class [005]
Pharmaceutical preparations for human use for the treatment of diseases, disorders and conditions related to pediatrics and neonatology, namely, respiratory diseases and disorders and their symptoms, immune system related diseases and disorders, namely, immunosuppressants, immunologic diseases and disorders, namely, autoimmune diseases and disorders, metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, and metabolic syndrome, cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders, oncological diseases and disorders, inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, and synovitis, blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood, musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis, ophthalmology, dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases, hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders, gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, genitourinary diseases, namely, urological diseases and disorders, prostatitis, nephritis, cystitis, vaginitis, and renal disease, damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne, inflammatory connective tissue diseases and injuries, malaria, tuberculosis, Allergy medications, Vaccines, namely, prophylactic and therapeutic vaccines for humans, neurological diseases and disorders, namely, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, and insomnia, central nervous system diseases and disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders, namely, schizophrenia and psychoses, muscular dystrophy; biologic preparations for medical and therapeutic purposes for the treatment of diseases, disorders and conditions related to pediatrics and neonatology, namely, respiratory diseases and disorders and their symptoms, immune system related diseases and disorders, namely, immunosuppressants, immunologic diseases and disorders, namely, autoimmune diseases and disorders, metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, and metabolic syndrome, cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders, oncological diseases and disorders, inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, and synovitis, blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood, musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis, ophthalmology, dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases, hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders, gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, genitourinary diseases, namely, urological diseases and disorders, prostatitis, nephritis, cystitis, vaginitis, and renal disease, damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne, inflammatory connective tissue diseases and injuries, malaria, tuberculosis, Allergy medications, Vaccines namely prophylactic and therapeutic vaccines for humans, neurological diseases and disorders namely migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, and insomnia, central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses, muscular dystrophy

Classification kind code

11

Class [042]
Scientific and technological services and research and design relating thereto, namely, medical research, scientific research and analysis in the fields of diseases, disorders and conditions related to pediatrics and neonatology, pharmaceuticals, biomedicine, clinical trials and post-market trials; pharmaceutical, biomedical and biological therapeutic research services; research in the fields of pharmaceutical and biologic therapeutic preparations, clinical trials and post-market trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticals, biomedicine, clinical trials and post-market trials.

Classification kind code

11

Class [044]
Providing health and medical information in the fields of diseases, disorders and conditions related to pediatrics and neonatology, pharmaceuticals, biomedicine, clinical trials and post-market trials; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions.

Classification kind code

11

Mark Details

Serial Number

1941251

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 26
on 15th Aug 2022		Approved
Submitted for opposition 23
on 28th Jul 2022		Default Removed
Submitted for opposition 14
on 9th Jun 2022		Default Notice Sent
Submitted for opposition 15
on 9th Jun 2022		Correspondence Created
Submitted for opposition 15
on 14th Jan 2022		Correspondence Created
Submitted for opposition 22
on 31st Aug 2021		Search Recorded
Submitted for opposition 20
on 31st Aug 2021		Examiner's First Report
Submitted for opposition 31
on 22nd Jan 2019		Formalized
Submitted for opposition 1
on 18th Jan 2019		Created
Submitted for opposition 30
on 17th Jan 2019		Filed